Solace Biotech produces two bilayered tablet medications for treating diabetes that begin with G. Glymon-G1 contains 1 mg of glimepiride and 500 mg of extended release metformin. Glymon-G2 contains 2 mg of glimepiride and 500 mg of extended release metformin. Both glimepiride and metformin work to lower blood glucose levels. Glimepiride does so by stimulating the release of insulin from pancreatic beta cells, while metformin improves glucose tolerance by decreasing hepatic glucose production and intestinal glucose absorption while increasing peripheral glucose uptake and utilization.

1. Solace Biotech
Product s

2. Name of BraNds start
With alphaBet “G”

3. Glymon –G1
Glymon – G2
G

5. Glymon – G1 Bilayered
Tablets
Each bilayered tablet contains:
Glimepiride 1 mg
Metformin (sustained release) 500 mg
Anti-diabetic

6. DESCRIPTION:
Glimepiride
The primary mechanism of action of glimepiride in lowering blood glucose appears to be dependent
on
stimulating the release of insulin from functioning pancreatic beta cells. In addition, extra pancreatic
effects
may also play a role in the activity of sulphonylureas such as glimepiride.
Metformin
Metformin is an oral antihyperglyacemic drug used in the management of type 2 diabetes. It improves
glucose tolerance in patients with type 2 diabetes (NIDDM).
Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose,
improves
insulin sensitivity by increasing peripheral glucose uptake and utilization.

8. Glymon – G2 Bilayered
Tablets
Each bilayered tablet contains:
Glimepiride 2 mg
Metformin (sustained release) 500 mg
Anti-diabetic

9. DESCRIPTION:
Glimepiride
The primary mechanism of action of glimepiride in lowering blood glucose appears to be dependent
on
stimulating the release of insulin from functioning pancreatic beta cells. In addition, extra pancreatic
effects
may also play a role in the activity of sulphonylureas such as glimepiride.
Metformin
Metformin is an oral antihyperglyacemic drug used in the management of type 2 diabetes. It improves
glucose tolerance in patients with type 2 diabetes (NIDDM).
Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose,
improves
insulin sensitivity by increasing peripheral glucose uptake and utilization.

10. DESCRIPTION:
Glimepiride
The primary mechanism of action of glimepiride in lowering blood glucose appears to be dependent
on
stimulating the release of insulin from functioning pancreatic beta cells. In addition, extra pancreatic
effects
may also play a role in the activity of sulphonylureas such as glimepiride.
Metformin
Metformin is an oral antihyperglyacemic drug used in the management of type 2 diabetes. It improves
glucose tolerance in patients with type 2 diabetes (NIDDM).
Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose,
improves
insulin sensitivity by increasing peripheral glucose uptake and utilization.